Home › Research › Treatments
Antibody Therapies Targeting Amyloid-β and Tau in Alzheimer's Disease with Insights on Mechanisms, Clinical Trials, and Challenges
Ashesh AM, Gupta S, Jawaid T, Wal P, Bhise MR, Kumar A, Gasmi A.. Current topics in medicinal chemistry, 2026-02-19
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Lecanemab showed a statistically significant, although clinically modest, slowing of decline on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) in the 18-month double-blind, placebocontrolled trial. Clinical worsening was reduced by 27% when compared to placebo (mean difference of -0.45; 95% CI: -0.67 to -0.23). The change in CDR-SB fell short of the minimal clinically significant difference that is frequently mentioned for this patient population, and the observed clinical benefit is typically characterized as small to moderate. The results demonstrate lower Aβ and tau, a real therapeutic advantage, going beyond simple alterations in biomarkers, representing a major breakthrough in the treatment of AD. This review provides a summary of mechanisms, results of the clinical trials of anti-tau and anti-Aβ antibody treatments up to February 2024, as well as recommendations for their future developments.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ashesh, A. M., Gupta, S., Jawaid, T., Wal, P., Bhise, M. R., Kumar, A., et al. (2026). Antibody Therapies Targeting Amyloid-β and Tau in Alzheimer's Disease with Insights on Mechanisms, Clinical Trials, and Challenges. Current topics in medicinal chemistry. https://doi.org/10.2174/0115680266418206251122102530
Vancouver
Ashesh AM, Gupta S, Jawaid T, Wal P, Bhise MR, Kumar A, et al. Antibody Therapies Targeting Amyloid-β and Tau in Alzheimer's Disease with Insights on Mechanisms, Clinical Trials, and Challenges. Current topics in medicinal chemistry. 2026. doi:10.2174/0115680266418206251122102530. PMID: 41735210.
BibTeX
@article{ashesh2026-41735210,
author = {Ashesh, A. M. and Gupta, S. and Jawaid, T. and Wal, P. and Bhise, M. R. and Kumar, A. and Gasmi, A.},
title = {{Antibody Therapies Targeting Amyloid-β and Tau in Alzheimer's Disease with Insights on Mechanisms, Clinical Trials, and Challenges}},
journal = {Current topics in medicinal chemistry},
year = {2026},
doi = {10.2174/0115680266418206251122102530},
pmid = {41735210},
url = {https://doi.org/10.2174/0115680266418206251122102530}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Lecanemab showed a statistically significant, although clinically modest, slowing of decline on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) in the 18-month double-blind, placebocontrolled trial.
- Clinical worsening was reduced by 27% when compared to placebo (mean difference of -0.45; 95% CI: -0.67 to -0.23).
- The change in CDR-SB fell short of the minimal clinically significant difference that is frequently mentioned for this patient population, and the observed clinical benefit is typically characterized as small to moderate.
- The results demonstrate lower Aβ and tau, a real therapeutic advantage, going beyond simple alterations in biomarkers, representing a major breakthrough in the treatment of AD.
- This review provides a summary of mechanisms, results of the clinical trials of anti-tau and anti-Aβ antibody treatments up to February 2024, as well as recommendations for their future developments.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designclinical trial
- Effect sizereduced by 27%; 21.5%
- Evidence strengthLow
How this study scored 47/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 27 of the 58 points we could judge it on, which is 47 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Current topics in medicinal chemistry) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41735210) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 27 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 27 of the 58 points we could judge it on is 47 out of 100. |
| Total | 47 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “challenges”
2 studies in the library carry the topic tag “challenges”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.